Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | ALPG | P10696 | 1/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.54 |
| ▸ | PRF1 | P14222 | 3/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587016 | 0.86 | MEN1 (0.76) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL13587013 | 0.80 | KMT2A (0.67) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL14448899 | 0.75 | EGFR (0.65) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL4035641 | 0.75 | KMT2A (0.65) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL6000993 | 0.75 | EGFR (0.65) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL13056365 | 0.75 | PRF1 (0.60) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL9245688 | 0.74 | CISD1 (0.59) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL9245683 | 0.74 | CISD1 (0.59) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL4038510 | 0.73 | MEN1 (0.58) | MEN1KMT2AALPLHSP90AA1ALPI | |
| SCHEMBL18882615 | 0.72 | MEN1 (0.56) | MEN1KMT2AALPLHSP90AA1ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285802-B1 | OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | ASTEX PHARMACEUTICALS INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8759384-B2 | Oxo-imidazolyl compounds | ASTEXPHRMACEUTICALS, INC. | 2014-06-24 | — | — | US | disclosed |
| US-8759384-B2 | Oxo-imidazolyl compounds | ASTEXPHRMACEUTICALS, INC. | 2014-06-24 | — | — | US | disclosed |
| US-20140073639-A1 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | THE ROCKEFELLER UNIVERSITY (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073639-A1 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | THE ROCKEFELLER UNIVERSITY (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2014026009-A2 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | AVACYN PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | ASTEXPHRMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | ASTEXPHRMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| EP-1109580-A4 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6440985-B1 | Methods for treating viral infections | VIROPHARMA INCORPORATED | 2002-08-27 | — | — | US | disclosed |
| EP-1109580-A1 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000013708-A1 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | GALE, CYP51A1, GNE | MEN1 2988/4885KMT2A 2066/4885ALPL 58/4885 |
| US-20140073639-A1 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | GALE, ENGASE, MGAM | MEN1 4627/4885KMT2A 2869/4885ALPL 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.